Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026)
Zoetis' (ZTS) quarterly Liabilities and Shareholders Equity came in at $15.2 billion in Q1 2026, up 7.49% year-on-year from $14.1 billion in Q1 2025, and down 2.17% on a QoQ basis from $15.5 billion in Q4 2025.
Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $15.2 billion in Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 7.49% year-over-year to $15.2 billion in Q1 2026; TTM through Mar 2026 was $60.3 billion, a 6.09% increase from a year earlier, with the FY2025 full-year figure at $15.5 billion, up 9.08% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $15.2 billion, down from $15.5 billion in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for ZTS reached as high as $15.5 billion in Q4 2025 and fell as low as $13.7 billion in Q3 2022.
- Historically, Liabilities and Shareholders Equity has averaged $14.3 billion across 5 years, with a median of $14.2 billion in 2024.
- Across the five-year window, Liabilities and Shareholders Equity fell 4.28% in 2023 and grew 9.08% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $14.9 billion in 2022, then slipped by 4.28% to $14.3 billion in 2023, then declined by 0.6% to $14.2 billion in 2024, then climbed by 9.08% to $15.5 billion in 2025, then decreased by 2.17% to $15.2 billion in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $15.2 billion in Q1 2026, $15.5 billion in Q4 2025, and $15.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 6.71 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 25.35 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 928.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.15 Bn |
| Dec 31, 2025 | 15.49 Bn |
| Sep 30, 2025 | 15.16 Bn |
| Jun 30, 2025 | 14.48 Bn |
| Mar 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 14.20 Bn |
| Sep 30, 2024 | 14.36 Bn |
| Jun 30, 2024 | 14.17 Bn |
| Mar 31, 2024 | 14.35 Bn |
| Dec 31, 2023 | 14.29 Bn |
| Sep 30, 2023 | 14.11 Bn |
| Jun 30, 2023 | 13.75 Bn |
| Mar 31, 2023 | 13.75 Bn |
| Dec 31, 2022 | 14.93 Bn |
| Sep 30, 2022 | 13.67 Bn |
| Jun 30, 2022 | 13.77 Bn |
| Mar 31, 2022 | 13.86 Bn |
| Dec 31, 2021 | 13.90 Bn |
| Sep 30, 2021 | 13.71 Bn |
| Jun 30, 2021 | 14.07 Bn |